Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-155
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
CD47/TNFAIP8
Cancer name
Multiple Myeloma
Cancer site
Multiple Myeloma
Treatment type
Chemotherapy
Drug
Bortezomib
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-155 overexpression also re-sensitized drugresistant myeloma cells to bortezomib leading to cell death through targeting TNFAIP8.
Tissue resource
multiple myeloma pathologic specimens
multidrug-resistant multiple myeloma cell lines RPMI-8226-R5
multiple myeloma cell lines RPMI-8226
multiple myeloma cell lines MM.1S
multiple myeloma cell lines MM.1R
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
University of Toronto
H.Lee Moffitt Cancer Center and Research Institute
Country
Canada
USA
Continent
North American
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.